<DOC>
	<DOCNO>NCT01064856</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety adalimumab 40 mg administer every week ( eow ) subcutaneously ( SC ) compare placebo 12 week follow open label ( OL ) safety efficacy assessment participant non-ankylosing spondylitis ( AS ) , non-psoriatic arthritis ( PsA ) active peripheral spondyloarthritis ( SpA ) inadequate response &gt; = 2 non-steroidal anti-inflammatory drug ( NSAIDs ) , intolerant , contraindication , NSAIDs .</brief_summary>
	<brief_title>Study Adalimumab Participants With Peripheral Spondyloarthritis ( SpA )</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult participant inadequate response &gt; = 2 nonsteroidal antiinflammatories ( NSAIDs ) Participants arthritis enthesitis dactylitis plus : meet spondyloarthritis clinical criterion Negative purify protein derivative ( PPD ) test Chest XRay perform Baseline Visit Negative Ability administer subcutaneous injection General good health Prior antitumor necrosis factor ( TNF ) therapy Psoriasis Psoriatic Arthritis Fulfillment modify New York criterion Ankylosing Spondylitis Recent infection require treatment Significant medical event condition put patient risk participation Female participant pregnant breastfeed consider become pregnant study History cancer , except successfully treat skin cancer Recent history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>peripheral spondyloarthritis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>humira</keyword>
</DOC>